Leader in drug containment, drug delivery and diagnostic solutions for the pharmaceutical industry, Stevanato Group delivers integrated portfolio of products, processes and services that meet customer needs form the development to clinical and commercial stages. The company recently announced the acquisition of a facility located in Zhangjiagang near the existing drug containment solutions facility.
To meet the growing demand in the vaccine and biotech market, this state-of-the-art facility will be dedicated to the production of high value solutions such as pre-filled syringes and vials. The plant will also include a manufacturing area for visual inspection machines and glass forming lines and employ 270 people.
The beginning of the renovation is expected in spring 2022 and the equipment production in 2023. In the same time, the company will extend its current production site to double its production capacity. “We are excited to continue our expansion in China as part of our strategic priorities to optimize global footprint,” said Franco Moro, Chief Executive Officer of Stevanato Group. “Beginning construction on our new manufacturing hub is an important milestone for Stevanato Group in a key market, and will allow us to better serve local customers with premium drug containment solutions and machinery supply.” Part of the latest phase of Stevanato’s expansion in China, this new facility should be operative by 2024.